Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (15,8 Mio. €): Leberuntersuchung: Marker-Dienstprogramm bei Steatohepatitis testen Hor31.10.2017 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Leberuntersuchung: Marker-Dienstprogramm bei Steatohepatitis testen
Strongly associated with the epidemics of obesity and type 2 diabetes that are testing healthcare systems worldwide, Non-Alcoholic Fatty Liver Disease (NAFLD) is an increasingly common cause of advanced liver disease that is characterized by substantial inter-patient variability in severity and rate of progression. It is currently assessed by liver biopsy, an invasive, costly and risky procedure. The lack of noninvasive biomarkers has hampered patient care and impeded drug development by complicating conduct of clinical trials.The overarching aim of LITMUS is to develop, robustly validate and advance towards regulatory qualification biomarkers that diagnose, risk stratify and/or monitor NAFLD/NASH progression and fibrosis stage. This will be achieved through a goal-oriented, tri-partite collaboration delivering a definitive and impartial evaluation platform for biomarkers, bringing together: (i) End-users of biomarker technologies (clinicians with expertise in NAFLD and the pharmaceutical industry)? (ii) Independent academics with expertise in the evaluation of medical test/biomarker performance? and (iii) Biomarker researchers and developers (academic or commercial). LITMUS has the demonstrable capability to fulfil the IMI call remit. Built upon foundations laid by the EU-funded FLIP/EPoS projects and long-established, successful scientific collaborations amongst many of Europe’s leading clinical-academic centres, LITMUS is at a unique advantage due to its existing large-scale patient cohorts, bioresources and multi-omics datasets. Consortium members are internationally recognised experts with substantial relevant expertise supporting the program’s clear focus on biomarker identification, validation and accelerating EMA/FDA qualification. Thus, LITMUS is powered to provide clarity on biomarker validity for NAFLD at scale and pace: supporting drug development and the targeting of medical care and limited healthcare resources to those at greatest need.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Abbvie Inc. | 0,00 € |
| Allergan Ltd. | 0,00 € |
| Antaros Medical AB | 231.275 € |
| 403.018 € | |
| Assistance Publique Hopitaux de Paris | 323.000 € |
| Astrazeneca AB | 0,00 € |
| 0,00 € | |
| Bristol-Myers Squibb Company Corp. | 0,00 € |
| Consiglio Nazionale Delle Ricerche | 0,00 € |
| EUROPEAN Association FOR THE STUDYOF THE LIVER | 61.680 € |
| 0,00 € | |
| Echosens | 0,00 € |
| Eli Lilly and Company Ltd. | 0,00 € |
| 0,00 € | |
| 118.350 € | |
| 78.488 € | |
| Faculdade de Farmácia da Universidade de Lisboa | 56.969 € |
| Fondation Cardiometabolisme Nutrition | 621.750 € |
| Genfit | 0,00 € |
| Gilead Sciences Inc. | 0,00 € |
| HELSINGIN YLIOPISTO | 202.500 € |
| Histoindex PTE Ltd. | 0,00 € |
| Intercept Pharma Europe Ltd. | 0,00 € |
| Ixscient Ltd. | 344.375 € |
| 99.600 € | |
| Luxembourg Institute OF Health | 540.034 € |
| Medizinische Universitaet Wien | 1.944,86 € |
| NOVARTIS PHARMA AG | 0,00 € |
| Nordic Bioscience A/S | 1.427.093 € |
| Novo Nordisk A/S | 0,00 € |
| ONE WAY Liver SL | 1,00 € |
| Orebro University | 312.500 € |
| Perspectum Ltd. | 257.500 € |
| Pfizer Ltd. | 0,00 € |
| 0,00 € | |
| 0,00 € | |
| SANOFI-AVENTIS DEUTSCHLAND GmbH | 0,00 € |
| 601.250 € | |
| Somalogic Inc. | 0,00 € |
| Sorbonne Universite | 0,00 € |
| Stichting Amsterdam UMC | 1.180.910 € |
| TAKEDA PHARMACEUTICALS INTERNATIONAL AG | 0,00 € |
| Takeda Development Centre Europe Ltd. | 0,00 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 598.005 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 1.811.250 € |
| The University of Birmingham | 61.264 € |
| The University of Nottingham | 118.115 € |
| UNIVERSITAET BERN | 435.000 € |
| UNIVERSITAETSKLINIKUM AACHEN | 248.076 € |
| UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT | 406.206 € |
| UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ | 1.073.015 € |
| Universita Cattolica Del Sacro Cuore | 80.654 € |
| Universita Degli Studi DI Firenze | 0,00 € |
| Universita Degli Studi DI Milano | 80.723 € |
| Universita Degli Studi DI Palermo | 105.081 € |
| Universita Degli Studi DI Torino | 365.161 € |
| Universitair Medisch Centrum Utrecht | 273.329 € |
| Universitair Ziekenhuis Antwerpen | 167.100 € |
| Universite d'Angers | 122.500 € |
| University of Newcastle Upon Tyne | 2.990.166 € |
Quelle: https://cordis.europa.eu/project/id/777377
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Abbvie Inc. - EU-Förderung (15,8 Mio. €): Leberuntersuchung: Marker-Dienstprogramm bei Steatohepatitis testen"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
